Background: Surgery is the only therapy with potentially curative intention in pancreatic cancer. This analysis aimed to determine prognostic parameters in a patient cohort with resected pancreatic adenocarcinoma with a special focus on the revised R1-definition. Methods: Between October 2001 and August 2009, data from 1071 consecutively resected patients with pancreatic adenocarcinoma were prospectively collected in an electronical database. Parameters tested for survival prediction in univariate analysis included patient, tumor, and resection characteristics as well as adjuvant therapy. The parameters with significant results were used for multivariate survival analysis. Identified parameters with positive or negative prognostic effect were used to define risk groups and to assess the effects on patient survival. Results: Age, ASA-score, CEA and CA19-9 levels, preoperative insulindependent diabetes mellitus, T-, N-, M-, R-, G-tumor classification, advanced disease, and LNR were all significant in univariate analysis, whereas gender, NYHA score, BMI, insurance status, type of surgical procedure, and adjuvant therapy were not. In multivariate analysis, age ≥70 years, preoperative insulin-dependent diabetes, CA19-9 ≥400 U/mL, T4-, M1-or G3-status, and LNR > 0.2 were independent negative predictors, whereas Tis/T1/T2-status, G1-differentiation, and R0-status (revised definition) were independently associated with good prognosis. Using these risk factors, patients were stratified into 4 risk-groups with significantly different prognosis; 5-year survival varied between 0% and 54.5%. Risk stratification resulted in improved survival prognostication within the predominant AJCC IIA and AJCC IIB stages. Conclusions: A newly defined prognostic profiling including the revised R1-definition discriminates survival of patients with resectable pancreatic adenocarcinoma better than the AJCC staging system, and may be of particular relevance for patient-adjusted therapy in the heterogeneous group of AJCC stage II tumors.
or possibly also immunoradiochemotherapy may contribute to or even improve these results. [5] [6] [7] Prognosis of patients with pancreatic adenocarcinoma is defined by tumor stages according to the AJCC Cancer Staging Manual. 8 For pancreatic cancer, the last significant revision, published in 2002 (6th edition), 9 newly classified T4 tumors as those, which extend beyond the pancreas and involve the celiac axis or superior mesenteric artery. These tumors generally are deemed irresectable. However, recent studies which assessed the survival of patients with resected pancreatic carcinomas mixed old and new staging criteria, mostly due to prolonged acquisition periods of tumor registry databases, 8, 10 or are based on relatively small patient cohorts. 11, 12 Therefore, suggested nomograms, implemented additional prognostic parameters, or risk models may be of only limited value for improved prognosis estimation of patients with resected pancreatic adenocarcinoma which are classified according to the current TNM staging system. This analysis aims to determine prognostic parameters for patients with resected pancreatic adenocarcinoma. Patients have all been treated by a highly standardized surgical strategy within a relatively short period of time and have all been classified by the current AJCC 2010 cancer staging system. Including the revised R1-definition, 13, 14 which applied a standardized examination of resection specimens with inking of the resection margins and defined R1 as a distance of the tumor from the resection margin of ≤1 mm, we identified prognostic parameters which provide additional information for improved prognosis estimation, in particular for the largely heterogeneous group of patients with resectable locoregional pancreatic cancer.
PATIENTS AND METHODS Patient Selection
A total of 1071 consecutive patients who underwent pancreatic resection for primary pancreatic adenocarcinoma were identified from a prospectively maintained database of 2633 pancreatic resections that were undertaken between October 2001 and August 2009 at the Department of General Surgery, University of Heidelberg, Germany. All tumors were classified according to the TNM criteria of the AJCC 2010 cancer system. 15 Those patients who were operated before the AJCC revision in 2002, 9 which newly defined T4 as tumors that infiltrate the superior mesenteric artery or the celiac trunk, were reclassified accordingly. Patients ± neoadjuvant chemoradiotherapy where histopathologic evaluation demonstrated tumor-free hepatic or mesenteric artery resection specimen were classified pT3. Patients with ampullary carcinomas or carcinomas of the distal bile duct were excluded from analysis. tumors were excluded from resection if the presence of metastatic disease was identified by presurgical imaging studies. Suspected ductal adenocarcinomas with singular liver metastasis as identified by preoperative cross-sectional imaging or intraoperatively were resected only in selected patients who were young or in otherwise extraordinary healthy condition. Patients with advanced locoregional disease and tumor propagation to the large arterial vessels were generally explored and eventually resected after neoadjuvant chemoradiation when patients were in generally good condition and distant metastasis had been ruled out by imaging studies. Adjuvant therapy was generally performed in all patients with histology-proven adenocarcinoma of the pancreas excluding those patients with a postoperatively poor Karnofsky index whose condition did not permit adjuvant therapy. Furthermore, adjuvant chemotherapy was applied selectively to patients with stage I IPMN-or MCN-associated carcinomas in the first years of the investigated period due to their supposedly more favorable tumor biology.
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Parameter Analysis
All parameters were prospectively collected in an electronic database. Possible determinants of patient survival were tested for patient, tumor, and resection characteristics. Patient characteristics included age, gender, insurance status, ASA score, NYHA score, presence of preoperative diabetes mellitus, body mass index (BMI), and serum levels of CEA and CA 19-9. Tumor and resection characteristics include tumor location and histology, type of resection, T-, N-, M-, R-, G-status, lymph node ratio (LNR), the number of lymph nodes evaluated, and the time of surgery in relation to the revised pathological specimen evaluation and R1-definition. The margin resection status (R-status) was defined according to general recommendations before June 2005 when R1 was defined as tumor formations invading the resection margin. Starting June 2005, pathologic reporting included a standardized examination of resection specimens with inking of the resection margins, and R1 was defined as a distance of the tumor from the resection margin of ≤1 mm.
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Follow-up
To assess long-term survival, data from our pancreatic outpatient clinic was used. For those patients whom were not included in our follow-up program, patients, general practitioners, relatives, and insurance companies were contacted by telephone and asked for patient survival, or the documented day of death. Follow-up was incomplete for 53 patients (5%). Of those, 36 patients were resected in 2009 and had a follow-up time of less than 6 months.
Statistical Analysis
SAS software (Release 9.1, SAS Institute, Inc, Cary, NC) was used for statistical analysis. The quantitative variables age, BMI, serum levels of CEA and CA 19-9, LNR, the number of lymph nodes evaluated, and follow-up time were expressed as median with interquartile range (IQR). Overall survival was defined as the time from the date of pancreatic resection to either death from any cause or last follow-up. Patients alive at the last follow-up were censored. Survival curves were constructed by using the Kaplan-Meier estimate. The 5-year survival rates and the median survival time are presented. Survival differences between subgroups of patients were analyzed by the log-rank test. Univariate associations between patient characteristics, tumor and resection characteristics and overall survival were assessed by Cox proportional hazards regression analysis. To confirm predictors of survival, all significant parameters were further examined by a multivariate Cox proportional hazards regression analysis among patients with complete data sets. Patients who died in the hospital or were lost to follow-up were excluded from analysis of prognostic factors. Two-sided P values were always computed and a difference was considered statistically significant at P < 0.05.
RESULTS
In an 8-year period, pancreatic resection was performed in 1071 patients with a primary pancreatic adenocarcinoma. Median age of patients was 65.4 years, and the male to female distribution was 56% to 44%. Patient characteristics including insurance status, comorbidity, BMI, and tumor markers are presented in Table 1 . Pancreatic head resections were performed in 712 patients (66.5%), distal pancreatectomies in 199 patients (18.6%), and total pancreatectomies in 160 patients (14.9%). The 30-day mortality rate was 2.2%.
The majority of patients had the tumor located in the head of the pancreas (73.2%), whereas multifocal lesions or tumors in the body or tail of the pancreas were almost equally distributed throughout the remaining patients (Table 2 ). Histopathologic evaluation identified predominantly ductal adenocarcinomas (in 90.3% of patients) and IPMN-based adenocarcinomas (in 5.8% of patients). Data on TNM and AJCC stage including information about the resection status and grading of the tumor is presented in Table 2 . Likewise, data on LNR in lymph node positive patients is shown in Table 2 . Overall, a median of 22 lymph nodes (interquartile range 15-29) has been resected and evaluated by pathology. Before the revision of the R1-definition in June 2005, more that 80% of resections where histopathologically margin negative, whereas this rate decreased to 36% in the second period ( Table 2) .
Median follow-up of patients alive at last contact was 17 months (range 1-92 months, interquartile range 10-31 months). Parameters tested for survival prediction in univariate analysis included all presented patient, tumor, and resection characteristics as well as adjuvant therapy. In univariate analysis, age ≥70 years, ASA 3/4 score, insulin-dependent diabetes mellitus, serum CEA level ≥5 μg/L, serum CA19-9 level ≥ 400 U/mL, advanced disease (T4, R2, or M1), T4-, N1-, M1-, R1/2-, G3/4-status, and a LNR > 0 were negative predictive factors for survival. IPMN-based adenocarcinomas (IPMCs), Tis/T1/T2-and revised R0-and G1-status were associated with good prognosis (Table 3 ). The parameters with no significant effects on survival were gender, health insurance status, BMI, NYHA-status, type of pancreatic resection, the number of lymph nodes resected and subsequently evaluated by pathology in the resection specimen, and adjuvant chemo-or radiochemotherapy. Importantly, the time of surgery, which is assessed in relation to the onset of the revised R1-definition, showed no significant effects on survival.
The parameters with significant results in univariate analysis were subsequently used for multivariate survival analysis in the Cox proportional hazards model. In this multivariate approach among 809 patients with complete data sets, age ≥70 years (P = 0.0045), the presence of preoperative insulin-dependent diabetes (P = 0.0094), serum CA19-9 levels of ≥ 400 U/mL (P < 0.0001), T4-(P < 0.0001), or M1-status (P < 0.0001), LNR > 0.2 (P < 0.0001), and G3-tumor differentiation (P < 0.0001) were independent negative predictors of survival (Table 4 , Figs. 1A-D) . Parameters which were independent positive predictors were Tis/T1/T2-and revised R0-status and G1-tumor differentiation ( (Fig. 1E ).
Patients were stratified according to the AJCC staging system ( Fig. 2A) and were grouped using the number of independent positive predictors (Tis/T1/T2, R0 revised, and G1; each weighted -1) and negative predictors (age > 70, preoperative IDDM, serum CA19-9 level ≥400 U/mL, T4-, G3/4-, M1-status, and LNR > 0.2; each weighted + 1) identified by multivariate analysis. Calculating the overall sum of the risk factors, 4 risk groups were identified with 5-year survival rates between 0% in the highest-risk group, 6.6% and 17.4% in the intermediate risk groups, and 54.5% in the lowest-risk group (Fig. 2B) . For the large groups of both AJCC IIA (17%) and IIB (65%) patients the prognosis was inhomogeneous. Additional information from identified prognostic markers allowed the stratification of these patients with significant survival differences within the AJCC stages. Whereas median survival and 5-year survival rate were 29.8 months and 23.6% for the AJCC IIA group, respectively, the risk stratification resulted in median survival between 16.5 and 36.8 months (Fig. 3A) . Likewise, in the AJCC IIB group which showed a median survival of 21.4 months and a 5-year survival rate of 9.6%, median survival varied in dependency of the number of prognostic factors between 10.3 and >50 months and 5-year survival rates between 0% and 59.8% (Fig. 3B ).
DISCUSSION
The study analyzed the survival of patients with resected primary adenocarcinoma of the pancreas. All patients have been treated at a high-volume single institution within a period of about 8 years. One thousand and seventy-one subsequent patients with major pancreatic resections who had the diagnosis of primary pancreatic adenocarcinoma in final histology were included in this analysis. A relatively standardized surgical approach at our center within this period was accompanied by a uniform tumor classification according to the AJCC staging system (6th edition, published in 2002 9 which is identical to the 7th edition, published in 2010 15 for pancreatic carcinomas). Because the T4 and AJCC stage III definitions for pancreatic cancer were newly defined in the AJCC 2002 system, all of our initially classified pT4 tumors (according to the AJCC criteria from 1997) were reclassified and remained pT4 only when the celiac axis or the superior mesenteric artery were infiltrated by tumor. Furthermore, due to our pancreatic center status and a progressive surgical attitude, patients with advanced locoregional disease who underwent multivisceral resections 19 and patients with resected limited metastasized disease 20 also were included in this analysis. Therefore, all stages of pancreatic cancer, which are resectable in potentially curative intention were included in this study.
The results of this study validate the 7th edition of the AJCC staging system for pancreatic carcinomas and demonstrate sufficient survival discrimination between the tumor stages. As published previously, 8 we confirmed that tumor size, nodal status, and distant metastasis were independent predictors of survival in patients who underwent pancreatic resection. Importantly, additional independent prognostic parameters were identified in our patient cohort: age older than 70 years, the preoperative presence of insulin-dependent diabetes mellitus, serum CA-19-9 levels above 400 U/mL, G3/4 tumor grading, and a LNR > 0.2 were negative predictors, and G1 tumor grading was a positive predictor. Importantly, the resection margin status was independently predictive in the multivariate Cox proportional hazards model only when the revised R-classification was applied. 13, 14 Therein, pathologic reporting included a standardized 3-dimentional examination of resection specimens with inking of the resection margins, and R1 was defined as a distance of the tumor from the resection margin of ≤1 mm. When a prognostic risk score was calculated using the overall sum of independent positive (risk weighted -1) and negative (risk weighted + 1) predictors identified by multivariate analysis, the survival discrimination between prognostic groups was superior to that in the AJCC staging system. For the entire cohort of patients with resected primary pancreatic adenocarcinomas, 4 risk groups were identified with 5-year survival rates varying between 0%, 6.6%, 17.4%, and a very good 54.6% from the highest-risk to the lowest-risk group, respectively. The identified prognostic parameters apart from the TNM-scoring provided additional relevant information for the predominant and largely heterogeneous group of AJCC stage II patients, which are classified according to the AJCC-classification into For risk stratification, patients were grouped using the number of independent positive predictors (Tis/T1/T2, R0 revised, and G1; risk weighted -1) and negative predictors (age > 70, preoperative IDDM, serum CA19-9 level ≥ 400 U/mL, T4-, G3/4-, M1-status, and LNR >0.2; risk weighted + 1).
stage IIA if nodal negative or stage IIB if nodal positive. Grouped according to the newly defined prognostic scoring system, median survival in the AJCC IIA stage varied between 36.8 months in the lowest risk group (<0 risk factors), 26.0 months for the intermediate risk group (0 or 1 risk factor), and 16.5 months in the highest risk group (2 or 3 risk factors). A similar good survival stratification was seen in the AJCC IIB group, with 5-year survival rates varying between 59.8%, 17.6%, 6.5%, and 0% in the groups with <0, 0, 1/2, and 3-5 risk factors, respectively. This clearly demonstrates the need to include additional patient and tumor parameters to predict more accurately patient survival in this group of resected locoregional pancreatic adenocarcinomas. As compared with the conventional AJCC staging system, this system may help to adjust adjuvant therapy to patient risk and tumor aggressiveness more properly. Negative predictive factors including high age, the preoperative onset of insulin-dependent diabetes mellitus, high serum CA-19-9 levels, and the presence of distant metastasis confirmed by intraoperative frozen section may also provide additional information for intraoperative decision making regarding the presumable benefit of potentially high-risk multivisceral pancreatic resections.
This analysis provides strong evidence that a previously suggested revision of the R1-definition, which includes a detailed 3-dimentional histopathologic evaluation of resection specimens, 13, 14 is mandatory to predict patient survival. Survival rates of R0-and R1 resections were almost identical applying the general R1-definition before June 2005, suggesting that the margin status is irrelevant because systemic failure determines outcome in the majority of patients. 21 Importantly, R0-resections according to the revised definition were associated with significantly better prognosis, but were achieved in only 36% of patients. This low rate of true R0-resections may possibly account for the generally high rate of local recurrences after pancreatic cancer resections. 22 Along with the TNM staging criteria, tumor grading was one of the strongest independent predictors of survival in our patient cohort. Whereas G1-differentiated tumors were characterized by significantly better median survival (43.5 months vs. 23.4 months, respectively) and 5-year survival rates (36.0% vs. 11.4%, respectively) as compared with G2 tumors, survival of G3/4 tumors was poor (median survival 15.2 months, 5-year survival rate 6.3%). Previously, the Memorial Sloan Kettering Cancer Institute group suggested a nomogram to better predict the likelihood of disease-specific survival after resection of pancreatic cancer, where the degree of tumor differentiation was included as one of the additional factors. 23 Likewise several other multivariate studies have shown that tumor grading is an important independent prognostic factor after pancreatic carcinoma resection. Analyzing 8082 patients with resected pancreatic cancer from the Surveillance, Epidemiology, and End Results (SEER) database, Wasif et al demonstrated that for each AJCC stage, survival was significantly worse for high-grade versus low-grade tumors, and that a high tumor grade was an independent predictor of survival for the entire cohort on multivariate analysis. 10 Summarizing the available evidence including our study, it seems essential to include tumor grading in improved prognostication models to reflect the aggressive biology of high-grade pancreatic adenocarcinomas.
Extended lymphadenectomy during pancreaticoduodenectomy neither had an effect on survival time in several randomized controlled trials, [24] [25] [26] nor did a metaanalysis demonstrate any survival benefit. 27 However, the presence of lymph node metastasis in pancreatic cancer is strongly associated with impaired survival. The 5-year survival rate decreased to 7,7% in nodal positive patients as compared with 26.6% in nodal negative patients in this analysis. In the heterogeneous group of nodal-positive patients, survival could further be stratified when the LNR was assessed. Whereas the 5-year survival rate was 12.2% in patients with a LNR <0.2, it decreased to 6.6% and 1.7% when the LNR was >0.2 to 0.4 or >0.4, respectively. Importantly, LNR was an independent predictor in multivariate analysis. In agreement with our analysis, several previous studies identified LNR as independent factor determining survival in resected pancreatic carcinomas. [28] [29] [30] Importantly, LNR must always be assessed in combination with the number of lymph nodes resected, because a low lymph-node retrieval may result in false-negative N0 findings. Reflecting the quality of lymphadenectomy at our center, a median of 22 resected and histophathologically evaluated lymph nodes was reported for the entire cohort, where also distal pancreatectomies with generally lower lymph node retrieval rates were included. This number seems favorable when compared with those reported in the extended lymphadenectomy groups of some randomized controlled trials for pancreaticodudenectomy 25, 26 or in the large SEER database. 31 Multiple studies have investigated tumor markers as possible predictors for survival in patients with pancreatic cancer, and the richest data is available on serum CA 19-9 levels. Using varying cut-off levels between 100 and 1,000 U/mL, a significant shorter postoperative survival of patients with high serum CA 19-9 levels was reported. [32] [33] [34] [35] In a study including 129 patients, Berger et al found lowest 5-year survival rates and shortest median survival in patients with serum CA 19-9 levels >200 U/mL as compared with those Copyright © 2011 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
FIGURE 2.
A and B, Survival of patients which were grouped according to the AJCC staging system (A, n = 968) and the number of risk factors identified by multivariate analysis (B, n = 809). Only patients with complete follow-up and data sets were included.
with moderately elevated (38-200 U/mL) or normal (<37 U/mL) CA 19-9 levels. 33 Including preoperative data from 887 patients, our data strongly supports this finding. With a cut-off point at 400 U/mL, high serum CA 19-9 levels were one of the strongest negative survival predictors in univariate as well as in multivariate analysis, with a hazard ratio of 1.5. Whether high serum CA 19-9 levels reflect tumor burden, tumor aggressiveness, or both is yet uncertain.
Diabetes mellitus may either be a risk factor for the development of pancreatic cancer 36 or the result of pancreatic cancer growth. 37, 38 For breast, prostate, as well as colorectal cancer there is good data that diabetes mellitus is a negative predictive marker for survival, 39, 40 whereas only limited data is available from smaller cohort studies for pancreatic cancer. 41, 42 Our analysis provides very strong evidence from uni-and multivariate analysis that a preoperative existing insulin-dependent diabetes mellitus is a negative predictor of survival in resected pancreatic adenocarcinomas. Interestingly, the prognosis of patients with a non insulin-dependent diabetes mellitus was comparable to those without any evidence of diabetes mellitus. Unlike preoperative insulin-dependent diabetes mellitus, an increased BMI was not a negative predictive factor.
There is ongoing controversy about the prognosis of pancreatic carcinomas which arise form intraductal papillary mucinocystic carcinomas (IPMCs) as compared with ductal adenocarcinomas. Some reports suggested a better prognosis for IPMCs, 16, 17 but this benefit may just be based on earlier tumor diagnosis and subsequently earlier tumor stages in IPMC resection specimens. 43, 44 In univariate analysis, our data demonstrated significant better survival of IPMCs compared with other adenocarcinomas of the pancreas, with a hazard ratio of 0.23. This prognostic benefit was not sustained in multivariate analysis. Therefore, this work clearly indicates that IPMCs and ductal adenocarcinoms have comparable survival estimates when tumors are corrected for TNM stage.
Several randomized controlled trials have produced strong evidence that have established adjuvant therapy as a cornerstone in the multimodal treatment of pancreatic cancer. 5, 7 Accordingly, the Copyright © 2011 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
majority of patients in this series has received adjuvant chemotherapy or chemoradiation, partially in the setting of randomized controlled trials. 16, 17, 45, 46 Surprisingly, this analysis did not demonstrate a beneficial effect of either adjuvant chemotherapy or chemoradiation. This finding may be explained by the heterogeneity of the "control" group, which mixed severely impaired patients who had a low Karnofsky index and whose condition did not permit adjuvant treatment combined with patients with favorable early stage mucinous carcinomas. [16] [17] [18] Therefore this result does not contradict the beneficial role of adjuvant therapy.
In summary, this single-center analysis is one of the largest to date, which investigated prognostic factors in patients with resected pancreatic adenocarcinomas. With all tumors being staged according to the current AJCC staging system, the study confirmed that tumor size, nodal status, and distant metastasis were independent predictors of patient survival. Additional independent prognostic parameters, including age older than 70 years, the preoperative presence of insulindependent diabetes mellitus, CA-19-9 serum levels above 400 U/mL, R0 resection status as classified by the revised definition, G1 tumor differentiation, and a LNR larger than 0.2 have been identified. Applying these independent predictors in a prognostic scoring model, risk groups were identified with improved prognostication compared with the AJCC system. This may have critical relevance for patientadjusted intraoperative decision making and adjuvant therapy which incorporates individual predicted survival.
